Aggressive Non-Hodgkin Lymphomas: It's Getting Personal
Major advances in gene expression and deep sequencing analyses have generated unprecedented insight into disease biology of non-Hodgkin lymphoma subtypes with important prognostic and therapeutic implications. This session will delineate evolving treatment strategies in mantle cell lymphoma and peripheral T-cell lymphoma and bring in focus circulating tumor DNA as biomarker for potential clinical application.
Dr. Jia Ruan will review most recent molecular profiling data of mantle cell lymphoma and its application in contemporary diagnosis, prognosis and treatment stratification. She will discuss current management approach in the upfront and relapse settings in the context of molecular biomarkers to correlate disease biology with treatment outcome. Dr. Ruan will then discuss ongoing and emerging clinical strategies incorporating molecular biomarkers to optimize therapy.
Dr. Neha Mehta-Shah will discuss current approaches for the treatment of common subtypes of peripheral T-cell lymphoma in the upfront setting as well as in the relapsed setting. She will review the biologic rationale for future therapeutic strategies in these rare but difficult-to-treat lymphomas. Dr. Mehta-Shah then will address ongoing and emerging trials aimed to improve the treatment of patients with PTCL in both upfront and relapsed settings.
Dr. David Kurtz will discuss the current and emerging data supporting circulating tumor DNA in aggressive NHLs. He will review the broad landscape of methodologies for detecting circulating DNA, focusing on their strengths and weaknesses. Dr. Kurtz will then review the potential uses of circulating tumor DNA in NHLs, including tumor genotyping, relapse detection, and early response prediction, with a focus on translation into the clinic.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members